Connect with us
Lung cancer is the leading cause of cancer death, and many patients do not respond to immunotherapy. Researchers from IBIMA Biomedical Research Institute of Málaga and...
Daiichi Sankyo presented new results on its DXd antibody-drug conjugates at WCLC25 in Barcelona, showcasing advances in small cell and non-small cell lung cancer. Highlights included...
Immuno-oncology and molecular oncology are two of Sanofi's most promising bets to tackle some of the most difficult-to-treat cancers. While immuno-oncology research is focused on finding...
The Liège-based biotech company PDC*line Pharma, which specializes in immuno-oncology, has initiated a Phase I/II study to evaluate a therapeutic vaccine against lung cancer. This cancer...
A new combination of drugs has brought good news for both ovarian and lung cancer patients.
The anti-smoking advocacy groups score a victory as tobacco companies are now mandated to disclose the dangers of smoking to the public.
Different studies link the use of talc-based products to ovarian cancers. However, results vary and are often inconclusive.